Status:
COMPLETED
Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Osteoporosis
Eligibility:
FEMALE
45-79 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess bone mineral density in patients switching from an oral bisphosphonate to zoledronic acid, compared to those staying on the oral bisphosphonate.
Eligibility Criteria
Inclusion
- Post-menopausal women between 45 and 79 years of age
- Must be osteopenic/osteoporotic
- Treatment with oral bisphosphonate for at least 1 year
Exclusion
- Any woman of child bearing potential
- Treatment with other bone active agents
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2005
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT00097812
Start Date
May 1 2004
End Date
December 1 2005
Last Update
April 27 2012
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
The Permanente Medical Group
Santa Rosa, California, United States, 95403
2
Colorado Center for Bone Research
Lakewood, Colorado, United States, 80227
3
Florida Medical Research Institute
Gainsville, Florida, United States, 32605
4
Radiant Research
Stuart, Florida, United States, 34996